WO1994024160A3 - Erythropoietin muteins with enhanced activity - Google Patents

Erythropoietin muteins with enhanced activity Download PDF

Info

Publication number
WO1994024160A3
WO1994024160A3 PCT/US1994/004361 US9404361W WO9424160A3 WO 1994024160 A3 WO1994024160 A3 WO 1994024160A3 US 9404361 W US9404361 W US 9404361W WO 9424160 A3 WO9424160 A3 WO 9424160A3
Authority
WO
WIPO (PCT)
Prior art keywords
epo
muteins
biological activity
enhanced activity
erythropoietin muteins
Prior art date
Application number
PCT/US1994/004361
Other languages
French (fr)
Other versions
WO1994024160A2 (en
Inventor
Jean-Paul R Boissel
H Franklin Bunn
Danyi Wen
Mark O Showers
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Priority to AU67097/94A priority Critical patent/AU6709794A/en
Publication of WO1994024160A2 publication Critical patent/WO1994024160A2/en
Publication of WO1994024160A3 publication Critical patent/WO1994024160A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Novel modifications of erytropoietin (Epo) which improve the biological activity of the protein are provided. The modified Epo proteins (Epo muteins) may be used in the same manner as has been demonstrated for wild type Epo, except that relatively smaller doses are required due to the enhanced biological activity. Methods of using the Epo muteins for treatment of blood disorders are provided. A method of obtaining additional Epo muteins with enhanced biological activity is also provided.
PCT/US1994/004361 1993-04-21 1994-04-21 Erythropoietin muteins with enhanced activity WO1994024160A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU67097/94A AU6709794A (en) 1993-04-21 1994-04-21 Erythropoietin muteins with enhanced activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4980293A 1993-04-21 1993-04-21
US08/049,802 1993-04-21

Publications (2)

Publication Number Publication Date
WO1994024160A2 WO1994024160A2 (en) 1994-10-27
WO1994024160A3 true WO1994024160A3 (en) 1995-01-05

Family

ID=21961825

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/004361 WO1994024160A2 (en) 1993-04-21 1994-04-21 Erythropoietin muteins with enhanced activity

Country Status (2)

Country Link
AU (1) AU6709794A (en)
WO (1) WO1994024160A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153407A (en) * 1992-07-28 2000-11-28 Beth Israel Deaconess Medical Center Erythropoietin DNA having modified 5' and 3' sequences and its use to prepare EPO therapeutics
US5614184A (en) * 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
EP0888385B1 (en) 1996-03-14 2003-08-20 Genentech, Inc. Gdnf receptor and uses thereof
GB2318352A (en) * 1996-06-25 1998-04-22 Dejan Markovic Polypeptides mimicking the activity of human erythropoietin
US6967092B1 (en) 1996-10-25 2005-11-22 Mc Kearn John P Multi-functional chimeric hematopoietic receptor agonists
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
EP1177285A1 (en) * 1999-05-07 2002-02-06 Genentech, Inc. Chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
US6555343B1 (en) 1999-05-07 2003-04-29 Genentech Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
KR100524041B1 (en) * 1999-05-07 2005-10-27 제넨테크, 인크. Novel Chimpanzee Erythropoietin (CHEPO) Polypeptides and Nucleic Acids Encoding the Same
US6831060B2 (en) 1999-05-07 2004-12-14 Genentech, Inc. Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
EP1228214A2 (en) * 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
EP2277889B1 (en) 2001-12-21 2014-07-09 Human Genome Sciences, Inc. Fusion proteins of albumin and interferon beta
CA2491567A1 (en) * 2002-07-01 2004-01-08 The Kenneth S. Warren Institute, Inc. Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
WO2004009627A1 (en) * 2002-07-19 2004-01-29 Cangene Corporation Pegylated erythropoietic compounds
WO2007052154A2 (en) * 2005-04-29 2007-05-10 University Of Medicine And Dentistry Of New Jersey Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) * 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2032600A2 (en) 2006-05-19 2009-03-11 Glycofi, Inc. Erythropoietin compositions
JP2010510794A (en) * 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド Modified erythropoietin polypeptide and therapeutic use thereof
CN102232085A (en) * 2008-09-26 2011-11-02 Ambrx公司 Modified animal erythropoietin polypeptides and their uses
AR113091A1 (en) * 2018-09-27 2020-01-22 Univ Nacional Del Litoral MODIFIED HUMAN ERYTHROPOYETIN
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0148605A2 (en) * 1983-12-13 1985-07-17 Kirin-Amgen, Inc. Production of erythropoietin
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
EP0409113A1 (en) * 1989-07-20 1991-01-23 BEHRINGWERKE Aktiengesellschaft Human erythropoietin muteins, their production and their use
WO1991005867A1 (en) * 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms
EP0427189A1 (en) * 1989-11-07 1991-05-15 Snow Brand Milk Products Co., Ltd. Modified forms of human erythropoietin and DNA sequences encoding genes which can express them

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0148605A2 (en) * 1983-12-13 1985-07-17 Kirin-Amgen, Inc. Production of erythropoietin
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
EP0357804A1 (en) * 1987-03-20 1990-03-14 Genetics Institute, Inc. Compositions containing modified erythropoietin
EP0409113A1 (en) * 1989-07-20 1991-01-23 BEHRINGWERKE Aktiengesellschaft Human erythropoietin muteins, their production and their use
WO1991005867A1 (en) * 1989-10-13 1991-05-02 Amgen Inc. Erythropoietin isoforms
EP0427189A1 (en) * 1989-11-07 1991-05-15 Snow Brand Milk Products Co., Ltd. Modified forms of human erythropoietin and DNA sequences encoding genes which can express them

Also Published As

Publication number Publication date
AU6709794A (en) 1994-11-08
WO1994024160A2 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
WO1994024160A3 (en) Erythropoietin muteins with enhanced activity
DK1394179T3 (en) Process for the preparation of erythropoietin free of animal proteins
AU2404688A (en) Polypeptides
AU5914590A (en) Muteins of human erythropoietin, the preparation thereof and the use thereof
CA2232789A1 (en) Method for treating alzheimer's disease using glial cell line-derived neurotrophic factor (gdnf) protein product
ATE82507T1 (en) MEDICAL USE.
IL95480A0 (en) Process for the preparation of cyclic amino acids,and intermediates
EP0354322A3 (en) Antidiabetic alpha-substituted phosphonates
FR2544984B1 (en) BROAD SPECTRUM OF DERMAL AND DERMATOLOGICAL OINTMENT, AND METHOD FOR PREPARING THE SAME
DK0572688T3 (en) Peptides, with organ-protective activity, method for their preparation and their use in therapy
EP0181634A3 (en) Synthetic gene for human lysozyme
NZ224295A (en) A method of producing native or physiologically active secondary structure in physiologically inactive proteins
NO180636C (en) Process for the preparation of a pure O-glycosylated IGF-1
DK354188D0 (en) GUANIDINOTHIAZOL COMPOUND, PROCEDURE FOR THE PREPARATION OF USE AND ITS USE AS AN INTERMEDIATE IN THE FAMOTID PROCESS
AU3749389A (en) Method for fractionating proteins of human milk leading to the production particularly of lactoferrine and alpha-lactalbumine, and products obtained
IE860212L (en) Polypeptide factors from colostrum
AU616667B2 (en) Monoclonal antibodies against e7 protein of human type 16 papillomavirus, a process for their preparation, and their use
ATE143809T1 (en) PLACENTA EXTRACT AND METHOD FOR THE PRODUCTION THEREOF
ATE108331T1 (en) USE OF TNF IN THE MANUFACTURE OF A MEDICATION FOR THE TREATMENT OF PSORIASIS.
DE68917379D1 (en) Process for the production of proteins similar to natural human apolipoprotein-E.
EP0320207A3 (en) Methods and compositions for activating the human insulin receptor kinase
FR2687544B1 (en) HIGH BREAD WITH NATURAL FERMENTS OF FRUITS AND PARTICULARLY GRAPES, AND METHOD FOR PRODUCING THE SAME.
EP0279244A3 (en) A composition for the treatment and stimulation of the hair growth
AU2459188A (en) Anticoagulative protein pp4-x, and its preparation and use
KR0140866B1 (en) Novel glucose isomerase enzymes and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA